Published April 7, 2026
| Version v1
Journal article
Open
Effectiveness of ribociclib in metastatic breast cancer in one hospital in Bulgaria—results from real-world clinical practice
Authors/Creators
- 1. Medical Oncology Clinic, MHAT Nadezhda, Sofia, Bulgaria|Faculty of Pharmacy, Medical University of Sofia, Sofia, Bulgaria
- 2. National Council on Prices and Reimbursement of Medicinal Products, Sofia, Bulgaria
- 3. Faculty of Pharmacy, Medical University of Sofia, Sofia, Bulgaria|National Council on Prices and Reimbursement of Medicinal Products, Sofia, Bulgaria
- 4. Medical Oncology Clinic, MHAT Nadezhda, Sofia, Bulgaria
Description
Real-world evidence (RWE) complements randomized clinical trial data by demonstrating treatment effectiveness in routine practice and unselected populations. Despite the broad use of ribociclib, real-world data remain limited, particularly in Eastern Europe. This retrospective single-center analysis evaluated outcomes in Bulgarian patients treated with ribociclib and compared them with national and international evidence.
Of 156 patients, 71.8% received first-line therapy, and 80.2% had ECOG performance status 0. The clinical benefit rate was 86.9% overall and 90.9% in the first line. Median progression-free survival was 17.7 months overall and 19.9 months in the first line. Outcomes were comparable to pivotal phase III trials and national real-world data. In the Bulgarian setting, early use of ribociclib in patients with favorable performance status may achieve results similar to or better than those observed in broader national cohorts, highlighting the importance of optimal patient selection and management.
Files
PHAR_article_190655.pdf
Files
(689.4 kB)
| Name | Size | Download all |
|---|---|---|
|
md5:3ca9f55e3f03aaeba2ad4aec27c2c702
|
616.6 kB | Preview Download |
|
md5:3d038d9ecae072c98b890a5104f14787
|
72.8 kB | Preview Download |
Additional details
References
- Bulgarian National Health Insurance Fund (2020) Reimbursement decision for ribociclib in HR+/HER2- advanced breast cancer. Sofia: NHIF.
- Cardoso F, Costa A, Norton L, Senkus E, Aapro M, André F, Barrios CH, Bergh J, Biganzoli L, Blackwell KL, Cardoso MJ, Cufer T, El Saghir N, Fallowfield L, Fenech D, Francis P, Gelmon K, Giordano SH, Gligorov J, Goldhirsch A, Harbeck N, Houssami N, Hudis C, Kaufman B, Krop I, Kyriakides S, Lin UN, Mayer M, Merjaver SD, Nordström EB, Pagani O, Partridge A, Penault-Llorca F, Piccart MJ, Rugo H, Sledge G, Thomssen C, Van'T Veer L, Vorobiof D, Vrieling C, West N, Xu B, Winer E (2014) ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2). The Breast 23: 489–502. https://doi.org/10.1016/j.breast.2014.08.009
- Cvetanović AS, Jankovic KB, Stojković AS, Živković ND, Kostić MS, Popović LS (2026) Real-World Clinical Experience of First-Line Ribociclib Combined with an Aromatase Inhibitor in Metastatic Breast Cancer. Cancers 18: 242. https://doi.org/10.3390/cancers18020242
- Dhungana R, Prasai P, Paudel B, Ranabhat K, Sapkota S, Shrestha S (2025) Efficacy and Safety of Ribociclib Plus Endocrine Therapy Versus Endocrine Therapy Alone in HR-Positive/HER2-Negative Breast Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Clinical Medicine Insights: Oncology 19: 11795549251402955. https://doi.org/10.1177/11795549251402955
- European Commission (2020) Europe's beating cancer plan. Luxembourg: Publications Office of the European Union.
- European Commission Joint Research Centre (2025a) Cancer burden statistics in the EU-27, 2024 estimates. Ispra: JRC.
- European Commission Joint Research Centre (2025b) Country Cancer Profile: Bulgaria 2025. Ispra: JRC.
- European Commission Joint Research Centre (2025c) JRC Country Cancer Profile Bulgaria – breast cancer infographic. Ispra: JRC.
- European Society for Medical Oncology (2025) ESMO Clinical Practice Guidelines: metastatic breast cancer. Lugano: ESMO
- Fernández-Cuerva C, Chinchilla-Alarcón T, Alcaraz-Sánchez JJ (2023) Real-world effectiveness of ribociclib in metastatic breast cancer patients: Does dose affect survival? Journal of Oncology Pharmacy Practice 29: 1619–1627. https://doi.org/10.1177/10781552221144280
- Fountzilas E, Koliou G-A, Vozikis A, Rapti V, Nikolakopoulos A, Boutis A, Christopoulou A, Kontogiorgos I, Karageorgopoulou S, Lalla E, Tryfonopoulos D, Boukovinas I, Rapti C, Nikolaidi A, Karteri S, Moirogiorgou E, Binas I, Mauri D, Aravantinos G, Zagouri F, Saridaki Z, Psyrri A, Bafaloukos D, Koumarianou A, Res E, Linardou H, Mountzios G, Razis E, Fountzilas G, Koumakis G (2020) Real-world clinical outcome and toxicity data and economic aspects in patients with advanced breast cancer treated with cyclin-dependent kinase 4/6 (CDK4/6) inhibitors combined with endocrine therapy: the experience of the Hellenic Cooperative Oncology Group. ESMO Open 5: e000774. https://doi.org/10.1136/esmoopen-2020-000774
- García-Trevijano Cabetas M, Lucena Martínez P, Jiménez Nácher I, Díaz Almirón M, Zamora Auñón P, Herrero Ambrosio A (2021) Real-world experience of palbociclib and ribociclib: novel oral therapy in metastatic breast cancer. International Journal of Clinical Pharmacy 43: 893–899. https://doi.org/10.1007/s11096-020-01193-z
- Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Paluch-Shimon S, Campone M, Petrakova K, Blackwell KL, Winer EP, Janni W, Verma S, Conte P, Arteaga CL, Cameron DA, Mondal S, Su F, Miller M, Elmeliegy M, Germa C, O'Shaughnessy J (2018) Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. Annals of Oncology 29: 1541–1547. https://doi.org/10.1093/annonc/mdy155
- Hortobagyi GN, Stemmer SM, Burris HA, Yap Y-S, Sonke GS, Paluch-Shimon S, Campone M, Blackwell KL, André F, Winer EP, Janni W, Verma S, Conte P, Arteaga CL, Cameron DA, Petrakova K, Hart LL, Villanueva C, Chan A, Jakobsen E, Nusch A, Burdaeva O, Grischke E-M, Alba E, Wist E, Marschner N, Favret AM, Yardley D, Bachelot T, Tseng L-M, Blau S, Xuan F, Souami F, Miller M, Germa C, Hirawat S, O'Shaughnessy J (2016) Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer. New England Journal of Medicine 375: 1738–1748. https://doi.org/10.1056/NEJMoa1609709
- IARC (2022) GLOBOCAN 2022: Bulgaria fact sheet – breast cancer. Lyon: International Agency for Research on Cancer.
- Manova M, Arabadjiev J, Mangaldzhiev R, Dudov A, Penchev D, Hemetsberger M, Sharkov A, Zidarova B, Apostolova D, Vasileva M, Terezova S, Vlaskovska M, Savova A (2023) Adequate effectiveness of ribociclib plus letrozole or fulvestrant in patients with advanced or metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer treated in routine Bulgarian clinical practice. Biotechnology & Biotechnological Equipment 37: 2268753. https://doi.org/10.1080/13102818.2023.2268753
- National Council on Prices and Reimbursement (2023) Post-marketing monitoring report for ribociclib in Bulgaria. Sofia: NCPhR.
- Osborne CK, Schiff R (2011) Mechanisms of Endocrine Resistance in Breast Cancer. Annual Review of Medicine 62: 233–247. https://doi.org/10.1146/annurev-med-070909-182917
- Provenzano L, Dieci MV, Curigliano G, Giuliano M, Botticelli A, Lambertini M, Rizzo G, Pedersini R, Sirico M, La Verde N, Gennari A, Zambelli A, Toss A, Piras M, Giordano M, Tagliaferri B, Generali D, Sartori D, Miliziano D, Menichetti A, Ligorio F, Zurlo C, Griguolo G, Berton Giachetti PP, Faso V, Corti C, Chiappe E, Scagnoli S, Pisegna S, Capasso C, De Angelis C, Arpino G, Criscitiello C, Guarneri V, Pruneri G, Mariani L, Vernieri C, Bianchini G, Munzone E, Marra A, Boldrini L, Carnevale Schianca A, Katrini J, Cona MS, Cantile V, Grieco A, Pirolo M, Zappulo M, De Giglio MAR, Laganà M, Cosentini D, De Giorgi U, Vingiani A, Belfiore A, Fotia G, Mazzoli G, Sposetti C, Abate A, Bianchessi V, Capri G, Bianchi GV, De Braud F, Baili P, Scaperrotta G, Depretto C, Lasagna A, Jacobs F, Ponzoni O, Maccarone S, Strina C, Coccato S, Coviello R (2025) Real-world effectiveness comparison of first-line palbociclib, ribociclib or abemaciclib plus endocrine therapy in advanced HR-positive/HER2-negative BC patients: results from the multicenter PALMARES-2 study. Annals of Oncology 36: 762–774. https://doi.org/10.1016/j.annonc.2025.03.023
- Queiroz MM, Sacardo KP, Ribeiro MF, Gadotti LL, Saddi R, Oliveira LJDC, Linck RDM, Cruz MRDS, Barroso-Sousa R, Sahade M, Correa TS, Mano MS, Suzuki DA, Shimada AK, Katz A (2023) Real-world treatment outcomes in HR+ HER2- metastatic breast cancer patients treated with CDK4/6 inhibitors: Results from a reference center in Brazil. Cancer Treatment and Research Communications 35: 100683. https://doi.org/10.1016/j.ctarc.2023.100683
- SABCS MONALEESA Update (2025) San Antonio Breast Cancer Symposium 2025: updated overall survival analyses from the MONALEESA programme.
- Slamon DJ, Neven P, Chia SKL, Jerusalem GHM, De Laurentiis M, Im S-A, Petrakova K, Bianchi GV, Martin M, Nusch A, Sonke GS, De La Cruz-Merino L, Beck JT, Wang C, Deore U, Chakravartty A, Zarate JP, Taran T, Fasching PA (2021a) Updated overall survival (OS) results from the phase III MONALEESA-3 trial of postmenopausal patients (pts) with HR+/HER2- advanced breast cancer (ABC) treated with fulvestrant (FUL) ± ribociclib (RIB). Journal of Clinical Oncology 39: 1001–1001. https://doi.org/10.1200/JCO.2021.39.15_suppl.1001
- Slamon DJ, Neven P, Chia S, Jerusalem G, De Laurentiis M, Im S, Petrakova K, Valeria Bianchi G, Martín M, Nusch A, Sonke GS, De La Cruz-Merino L, Beck JT, Ji Y, Wang C, Deore U, Chakravartty A, Zarate JP, Taran T, Fasching PA (2021b) Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival. Annals of Oncology 32: 1015–1024. https://doi.org/10.1016/j.annonc.2021.05.353
- Slamon DJ, Neven P, Chia S, Fasching PA, De Laurentiis M, Im S-A, Petrakova K, Bianchi GV, Esteva FJ, Martín M, Nusch A, Sonke GS, De La Cruz-Merino L, Beck JT, Pivot X, Vidam G, Wang Y, Rodriguez Lorenc K, Miller M, Taran T, Jerusalem G (2018) Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: MONALEESA-3. Journal of Clinical Oncology 36: 2465–2472. https://doi.org/10.1200/JCO.2018.78.9909
- TBCT Bulgaria (2024) Breast cancer screening and early diagnosis in Bulgaria – infographic. Sofia: Think-Tank for Breast Cancer in Transition.
- Tripathy D, Im S-A, Colleoni M, Franke F, Bardia A, Harbeck N, Hurvitz SA, Chow L, Sohn J, Lee KS, Campos-Gomez S, Villanueva Vazquez R, Jung KH, Babu KG, Wheatley-Price P, De Laurentiis M, Im Y-H, Kuemmel S, El-Saghir N, Liu M-C, Carlson G, Hughes G, Diaz-Padilla I, Germa C, Hirawat S, Lu Y-S (2018) Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. The Lancet Oncology 19: 904–915. https://doi.org/10.1016/S1470-2045(18)30292-4